Bee, J.; Shaforostova, I.; Hoffmann, M.; Bertschinger, M.; Seipel, K.; Bacher, U.; Pabst, T.
AL Amyloidosis Patients Continue to Benefit from HDCT/ASCT Consolidation in the Daratumumab Era. J. Clin. Med. 2026, 15, 1564.
https://doi.org/10.3390/jcm15041564
AMA Style
Bee J, Shaforostova I, Hoffmann M, Bertschinger M, Seipel K, Bacher U, Pabst T.
AL Amyloidosis Patients Continue to Benefit from HDCT/ASCT Consolidation in the Daratumumab Era. Journal of Clinical Medicine. 2026; 15(4):1564.
https://doi.org/10.3390/jcm15041564
Chicago/Turabian Style
Bee, Julia, Inna Shaforostova, Michèle Hoffmann, Martina Bertschinger, Katja Seipel, Ulrike Bacher, and Thomas Pabst.
2026. "AL Amyloidosis Patients Continue to Benefit from HDCT/ASCT Consolidation in the Daratumumab Era" Journal of Clinical Medicine 15, no. 4: 1564.
https://doi.org/10.3390/jcm15041564
APA Style
Bee, J., Shaforostova, I., Hoffmann, M., Bertschinger, M., Seipel, K., Bacher, U., & Pabst, T.
(2026). AL Amyloidosis Patients Continue to Benefit from HDCT/ASCT Consolidation in the Daratumumab Era. Journal of Clinical Medicine, 15(4), 1564.
https://doi.org/10.3390/jcm15041564
